Sign in

Trial result ·

Results of a Phase 1 Study Assessing the Effect of CIN-102, a Novel Formulation of the Dopamine Receptor Antagonist Domperidone Designed to Treat Gastroparesis, on Cardiac Repolarization in Healthy Volunteers.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This study tested CIN-102, a new form of the drug domperidone. It is being made for gastroparesis that keeps coming back. The aim was to check its effect on the heart's QT interval. The study took place in 62 healthy people. Each person got 4 single doses at different times, in random order. These were 30 mg CIN-102, 100 mg CIN-102, a dummy drug, and moxifloxacin. Moxifloxacin was used as a check on the test. Heart tracings and blood samples were taken at set times.

What they found

The study ruled out a QT change above 10 ms for both doses. This held at all time points tested. It held up to blood levels about 6 times the usual treatment level. The drug had no relevant effect on heart rate. It also had no relevant effect on how signals move through the heart. No one died, and no serious harms took place.

What it means for patients

The authors say CIN-102 did not change heart tracings in a meaningful way. This was true at normal doses and at higher doses. They see it as a possible drug for gastroparesis. They say it may carry less QT risk than the usual domperidone.

Why it is not certain yet

The study was in 62 healthy people, not people with gastroparesis. Each person got only single doses, not doses over many days. This is an early, phase 1 study. It did not test whether CIN-102 eases gastroparesis. The abstract does not show a direct test against the usual domperidone.

Source

Results of a Phase 1 Study Assessing the Effect of CIN-102, a Novel Formulation of the Dopamine Receptor Antagonist Domperidone Designed to Treat Gastroparesis, on Cardiac Repolarization in Healthy Volunteers.

PubMed · PMID 41797689

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Gastroparesis publications